Cochrane · systematic review · CD007287
Antigen‐specific active immunotherapy for ovarian cancer
Paijens, ST, Leffers, N, Daemen, T, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 5 · 71.4%Low 0 · 0%Moderate 0 · 0%High 2 · 28.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antigen‐specific immunotherapy for ovarian carcinoma
Population: ovarian carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tumour response | no estimate extracted | 17 studies · 355 participants | Very low |
Tumour response | no estimate extracted | 6 studies · 64 participants | Very low Downgraded: indirectness |
Post‐immunotherapy treatment response | no estimate extracted | 4 studies · 88 participants | Very low Downgraded: imprecision |
Survival | no estimate extracted | 3 studies · 1062 participants | High |
Survival | no estimate extracted | 6 studies · 1882 participants | High |
Antigen‐specific immunogenicity (humoral response) | no estimate extracted | 25 studies · 1521 participants | Very low |
Antigen‐specific immunogenicity (cellular response) | no estimate extracted | 40 studies · 966 participants | Very low |